Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.69 |
| ▸ | NCF1 | P14598 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12038517 | 1.00 | HRH3 (0.69) | HRH3NCF1ALDH1A1KDM4EHRH4 | |
| SCHEMBL18403966 | 0.98 | NCF1 (0.67) | HRH3NCF1ALDH1A1KDM4EHRH4 | |
| SCHEMBL20649086 | 0.84 | L3MBTL3 (0.58) | HRH3NCF1ALDH1A1KDM4EHRH4 | |
| SCHEMBL4277270 | 0.83 | HRH3 (1.00) | HRH3NCF1ALDH1A1KDM4EHRH4 | |
| SCHEMBL19241878 | 0.83 | HRH3 (0.59) | HRH3NCF1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19986930 | 0.83 | ALDH1A1 (0.65) | HRH3NCF1ALDH1A1KDM4EMEN1 | |
| SCHEMBL3338493 | 0.83 | LMNA (0.62) | HRH3NCF1ALDH1A1KDM4E | |
| SCHEMBL21238989 | 0.81 | POLB (0.66) | NCF1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6571942 | 0.81 | HRH3 (0.64) | HRH3NCF1ALDH1A1KDM4EHRH4 | |
| SCHEMBL20684919 | 0.81 | SIGMAR1 (0.59) | HRH3NCF1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285872-B | Indole-2-ketone derivative and preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-111285872-A | Indole-2-ketone derivative and preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| WO-2004039764-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-0823906-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-0850236-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2001-07-04 | — | — | EP | disclosed |
| US-5981520-A | USEFUL FOR TREATING ASTHMA, BRONCHOSPASM, ALLERGIES, ANXIETY, COUGHING OR PAIN | SCHERING CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5869488-A | Piperazino derivatives as neurokinin antagonists | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0850236-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997008166-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | HRH3 2185/4885NCF1 2086/4885ALDH1A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.